Check patentability & draft patents in minutes with Patsnap Eureka AI!

Combination therapy with glucagon and GLP-1 co-agonist for treating obesity

A technology for blood sugar control and dosage, applied in glucagon, drug combination, chemical instruments and methods, etc., can solve problems such as weight loss and unmet needs of patients

Pending Publication Date: 2022-07-15
免疫医疗有限责任公司
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] While some therapies are available for glycemic control, no current therapy achieves significant weight loss, which remains a significant unmet need for patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy with glucagon and GLP-1 co-agonist for treating obesity
  • Combination therapy with glucagon and GLP-1 co-agonist for treating obesity
  • Combination therapy with glucagon and GLP-1 co-agonist for treating obesity

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0106] Example 1: Combination of dapagliflozin and metformin dual therapy

[0107] A phase 2a randomized, placebo-controlled, double-binding study was conducted to demonstrate the efficacy of cotudolide in overweight / obese patients with type 2 diabetes mellitus (T2DM) treated with dapagliflozin and metformin dual therapy. Efficacy and safety in subjects.

[0108] (A) Subject

[0109] A total of 128 subjects agreed to participate in this study. This study included subjects with T2DM treated with metformin monotherapy or with metformin and dapagliflozin dual therapy. Subjects were screened according to the following inclusion and exclusion criteria.

[0110] Inclusion criteria:

[0111] · Male and female subjects aged ≥18 years at screening;

[0112] · Body mass index (BMI) of 25kg / m at screening 2 and 40kg / m 2 (inclusive) between;

[0113] The HbA1c range at screening was between 7.0% and 10.0% (inclusive);

[0114] Diagnosed with T2DM and treated with metformin monoth...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are methods of improving glycemic control, reducing body weight, and / or treating type 2 diabetes in a human patient comprising administering a GLP-1 / glucagon agonist peptide, dapagliflozin, and metformin.

Description

[0001] References to Sequence Listings Submitted Electronically [0002] The electronically filed Sequence Listing content of the ASCII text file filed with this application (name: Sequencelisting_ST25.txt; size: 1,763 bytes; and creation date: December 2, 2019) is hereby incorporated by reference in its entirety . Background technique [0003] The incidence of obesity and diabetes continues to rise in epidemic proportions. Diabetes is characterized by high levels of blood sugar due to defects in insulin production, insulin action, or both. Type 2 diabetes (T2DM) accounts for approximately 90% to 95% of all diagnosed diabetes cases, and the risk of developing type 2 diabetes increases with weight gain. The prevalence of type 2 diabetes in obese patients is three to seven times higher than in normal-weight adults with a body mass index (BMI) greater than 35kg / m 2 20 times more likely to have the disease. However, weight loss can improve, control or cure type 2 diabetes. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/435C07K14/605A61P3/04A61P3/10A61K38/00
CPCC07K14/605A61P3/10A61P3/04A61K38/26A61K31/7034A61K31/155A61K2300/00
Inventor A·弗洛尔P·阿姆贝里
Owner 免疫医疗有限责任公司
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com